This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Discover the top features of no annual fee travel rewards cards. Choose the best option for your travel needs.
17,312 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Investors are weighing bets on critical metals as supply chains shift and demand from EVs and renewables climbs. This...
Friday marks the first triple witching of 2026 as Iran tensions flare, prompting investors to brace for volatile move...
Public life tests more than reputations—it tests money boundaries too. This article uses the phrase 'mayor kept calli...
Geopolitics are shaping energy markets in real time. A fresh disruption from Iran adds a new layer of risk and opport...
When a major broker raises its bets on a fintech-insurer, investors take notice. This article breaks down the upgrade...
Pricing conversations in real estate have moved from fixed numbers to dynamic narratives driven by financing, data, a...
Nasdaq-100 levered ETFs are back in focus as markets swing. While 3x exposure offers amplified moves, daily resets ma...
Delek US shares jumped as crude and refining margins strengthened. This article breaks down the drivers, the risks, a...
A senior U.S. senator warns that college grad unemployment will surge as AI reshapes entry-level work, potentially up...
Microsoft is staring down a tough start to the year. Is the slide a red flag or a rare chance to buy a tech titan wit...
Volatility is real and headlines can be alarming. Yet many individual investors continue to buy stocks. This guide ex...